Aldosterone antagonists for preventing the progression of chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 4, 2014, Pages

  Bolignano, Davide ^a   Palmer, Suetonia C ^b   Navaneethan, Sankar D ^c   Strippoli, Giovanni F M ^d,e,f,g,h,i  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF BARI   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g UNIVERSITY OF SYDNEY   (Australia)

^h Diaverum   (Sweden)

ⁱ UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; KIDNEY FAILURE, CHRONIC; META ANALYSIS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPIRONOLACTONE;

EID: 84923834917     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007004.pub3     Document Type: Review

References (108)

1. Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases & Transplantation 2011;22(1):75-8. [MEDLINE: 21196617].
2. Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases 2010;55(4):671-81. [MEDLINE: 20097461].
3. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International 2006;70(12):2116-23. [MEDLINE: 17035949].
4. Bianchi S, Bigazzi R, Campese VM. Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology 2006;17(Abstracts):33A. [CENTRAL: CN-00615828].
5. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE 2011;6(11):e26904. [MEDLINE: 22073219].
6. Boesby L, Elung-Jensen T, Strandgaard S, Kamper A. Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus 2009;2(Suppl 2):ii882.
7. Chrysostomou A, Pedagogos E, Briganti E, Becker GJ. A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology 2005;10(Suppl 1):A137. [CENTRAL: CN-00602127].
8. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN 2006;1(2):256-62. [MEDLINE: 17699214].
9. Cohen DL, Sterling K, Townsend RR. Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology 2010;21(Abstracts):936A.
10. Cohen DL, Sterling KA, Townsend RR. Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension 2011;13(4 Suppl 1):A116.
11. Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, et al.Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology 2010;106(10):1505-11. [MEDLINE: 21059444].
12. Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology 2012;73(3):447-54. [MEDLINE: 21950312].
13. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology 2009;54(6):505-12. [MEDLINE: 19643310].
14. Hammer F, Edwards NC, Hughes BA, Steeds RP, Ferro CJ, Townend JN, et al.The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology 2010;73(5):566-72. [MEDLINE: 20550533].
15. Epstein M, Buckalew V, Martinez F. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]. American Journal of Hypertension 2002;15(4 Suppl 1):24A. [CENTRAL: CN-00689079].
16. Epstein M, Weinberger M, Lewin A, Martinez F, He W, Krause S. The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology 2003;14(Nov):6A. [CENTRAL: CN-00550622].
17. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al.Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN 2006;1(5):940-51. [MEDLINE: 17699311].
18. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al.Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research 2008;31(1):59-67. [MEDLINE: 18360019].
19. Furumatsu Y, Shoji T, Hayashi D, Tomida K, Kaneko T, Tsubakihara Y, et al.Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology 2004;15:58A. [CENTRAL: CN-00653797].
20. Furumatsu Y, Shoji T, Tomida K, Mikami S, Kaneko T, Togawa M, et al.Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology 2003;14(Suppl S):762A. [CENTRAL: CN-00653796].
21. Guney I, Selcuk NY, Altintepe L, Atalay H, Basarali MK, Buyukbas S. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Renal Failure 2009;31(9):779-84. [MEDLINE: 19925284].
22. Haykal WJ, Kuryata OV, Frolova EO, Shvedenko OO. The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi257.
23. Koroshi A, Idrizi A, Gjergji Z, Hoxha B, Emrullaj E, Spahia E, et al.Combination of angiotensin converting enzyme inhibitors with mineralocorticoid antagonists in diabetic nephropathy [abstract no: SU342]. NDT Plus 2010;3(Suppl 3):iii424. [EMBASE: 70484562].
24. Lv J, Qin S, Li Y, Zhang H, Liu L, Shi S, et al.Change of proteinuria after adding spironolactone ACE inhibitor or angiotensin receptor blockers in IGA nephropathy, a pilot study [abstract no: SA309]. NDT Plus 2009;2(Suppl 2):ii1029.
25. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology 2009;20(12):2641-50. [MEDLINE: 19926893].
26. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304].
27. Van Buren PN, Adams-Huet B, Toto RD. Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine 2010;58(8):950-6. [MEDLINE: 21030879].
28. Morales E, Huerta A, Gutierrez E, Gutierrez SE, Segura J, Praga M. The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. ?Cual es la opcion terapeutica mas eficaz]. Nefrologia 2009;29(5):421-9. [MEDLINE: 19820754].
29. Morales E, Huerta A, Gutierrez-Millet V, Gutierrez E, Gutierrez-Solis E, Hernandez E, et al.Antiproteinuric effect of Renin-Angiotensin-Aldosterone System (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus 2009;2(Suppl 2):ii882.
30. Morales E, Huerta A, Gutierrez-Solis E, Gutierrez E, Polanco N, Gutierrez-Millet V, et al.Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676].
31. Nielsen S, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, et al.Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: A randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia 2011;54(Suppl 1):S445.
32. Nielsen S, Persson F, Frandsen E, Sugaya T, Zdunek DW, Pedersen K, et al.Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology 2011;22(Abstracts):238A.
33. Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, et al.Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine 2012;29(8):e184-90. [MEDLINE: 22268920].
34. Ogawa S, Takeuchi K, Mori T, Nako K, Ito S. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clinical & Experimental Pharmacology & Physiology 2006;33(5-6):477-9. [MEDLINE: 16700881].
35. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005;28(9):2106-12. [MEDLINE: 16123474].
36. Saklayen M, Gyebi L, Tasosa J, Yap J. Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology 2006;17(Abstracts):157A. [CENTRAL: CN-00615896].
37. Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine 2008;56(4):714-9. [MEDLINE: 18382267].
38. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Parving HH. Beneficial impact of spironolactone in diabetic nephropathy. Kidney International 2005;68(6):2829-36. [MEDLINE: 16316360].
39. Schjoedt KJ, Rossing K, Tarnow L, Parving H. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology 2005;16:57A. [CENTRAL: CN-00689347].
40. Schjoedt KJ, Rossing K, Juhl TR. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International 2006;70(3):536-42. [MEDLINE: 16775595].
41. Smolen E, Nowicki M. Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv386. [CENTRAL: CN-00716094].
42. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical & Experimental 2006;55(12):1645-52. [MEDLINE: 17142138].
43. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology & Metabolism 2006;91(6):2214-7. [MEDLINE: 16569732].
44. Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, et al.Add-on spironolactone in patients with advanced chronic kidney disease treated with angiotensin II receptor blockers [abstract no: F-PO1840]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):525A.
45. Larczynski W, Tylicki L, Rutkowski P, Renke M, Rutkowski B. The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742].
46. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, et al.Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases 2008;52(3):486-93. [MEDLINE: 18423812].
47. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International 2007;72(9):1164-5. [MEDLINE: 17943159].
48. van den Meiracker AH, Baggen RG, Pauli S. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension 2006;24(11):2285-92. [MEDLINE: 17053552].
49. Zheng H, Qiu H, Liu X, Jiang B. Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy. Pharmaceutical Care & Research 2011;11(4):266-8. [EMBASE: 2011509942].
50. Epstein M, Alexander JC, Roniker B. Eplerenone, a new selective aldosterone receptor antagonist (SARA): efficacy in patients with mild to moderate hypertension [abstract no: A1640]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):322A-3A. [CENTRAL: CN-00445239].
51. Essaian A, Kaukov I, Karabayeva A, Kadinskaya M, Katysheva N. The influence of spironolactone on plasma level of plasminogen-activator inhibitor type 1 (PAI-1) in anuric hemodialysis patients [abstract no: SaP266]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi322. [CENTRAL: CN-00716089].
52. Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, et al.Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertension Research - Clinical & Experimental 2004;27(12):963-70. [MEDLINE: 15894837].
53. Horita Y, Tadokoro M, Taura K, Taguchi T, Miyazaki M, Kohno S. Aldosterone breakthrough during combined angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in patients with IgA nephropathy [abstract no: M-PO20083]. Nephrology 2005;10(Suppl 1):A37. [CENTRAL: CN-00740497].
54. Horita Y, Taura K, Taguchi T, Furusu A, Kohno S. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology 2006;11(5):462-6. [MEDLINE: 17014562].
55. Medeiros M, Ramirez S, Velasquez L, Hernandez AM, Valverde S, Vargas A, et al.Aldosterone blockade in children with chronic allograft nephropathy [abstract]. Pediatric Nephrology 2010;25(9):1808. [EMBASE: 70438169].
56. Medeiros M, Sosa J, Velasquez L, Hernandez M, Ramirez S, Valverde S, et al.Aldosterone blockade in children with chronic allograft nephropathy [abstract no: 1296]. American Journal of Transplantation 2010;10(Suppl 4):411.
57. Medeiros M, Velasquez-Jones L, Hernandez AM, Valverde S, Fuentes Y, Barrera-Chimal J, et al.Mineralocorticoid receptor blockade in children with chronic allograft injury [abstract]. Pediatric Transplantation 2013;17:71. [EMBASE: 71163526].
58. Medeiros M, Velasquez-Jones L, Maria HA, Ramirez S, Fuentes Y, Valverdes S, et al.Aldosterone blockade in children with chronic allograft nephropathy [abstract]. Pediatric Transplantation 2011;15:98-9. [EMBASE: 70508755].
59. Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. Hypertension 2009;53(5):754-60. [MEDLINE: 19307466].
60. Anonymous. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. [Retraction of Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M. Diabet Med. 2004 May;21(5):471-5; PMID: 15089793]. Diabetic Medicine 2006;23(7):818. [MEDLINE: 16842490].
61. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, et al.The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabetic Medicine 2004;21(5):471-5. [MEDLINE: 15089793].
62. Renke M, Tylicki L, Knap N, Rutkowski P, Neuwelt A, Larczynski W, et al.spironolactone attenuates oxidative stress in patients with chronic kidney disease. Hypertension 2008;52(5):e132-3. [MEDLINE: 18824658].
63. Rosado Rubio C, Alvarez Alejandre ML, Lopez de la Fuente R, Lerma Marquez JL, Gonzalez C. Is eplerenone a safe and effective antiproteinuric drug in elderly patients with stage 3 chronic kidney disease (CKD)? [abstract no: Sa026]. NDT Plus 2010;3(Suppl 3):iii35. [EMBASE: 70483492].
64. Schjoedt KJ, Christensen PK, Jorsal A, Boomsma F, Rossing P, Parving HH. Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. Nephrology Dialysis Transplantation 2009;24(11):3343-9. [MEDLINE: 19561152].
65. Schjoedt KJ, Rossing K, Christensen PK, Parving HH, Rossing P. Autoregulation of the glomerular filtration rate during spironolactone treatment [abstract no: PUB561]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):953A. [CENTRAL: CN-00689324].
66. Schmidt BM, Schneider A, Kalizki T, Rastatter A, Schwarz TK, Schmieder RE. Low dose spironolactone rapidly reduces left ventricular mass [abstract no: F-FC099]. Journal of the American Society of Nephrology 2005;16:60A. [CENTRAL: CN-00716088].
67. Schmidt B, Sammer U, Schaufele T, Schmieder R. Effects of aldosterone on kidney blood flow. Medizinische Klinik 2005;100(Abstract-Band):68. [CENTRAL: CN-00777290].
68. Schmidt BM, Raff U, Schwab J, Bar I, Schmieder RE. Eplerenone at low dose induces regression of left ventricular hypertrophy in resistant hypertension [abstract no: SA-PO2251]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):617A.
69. Shahbazian H, Mousavi SB, Ehsanpour A, Danesh M. Spironolactone effect on preventing proteinuria in chronic kidney disease [abstract no: Su354]. NDT Plus 2010;3(Suppl 3):iii427. [EMBASE: 70484574].
70. Swift PA, Markandu ND, Wood M, Sagnella GA, MacGregor GA. A double blind randomized crossover trial of amiloride and spironolactone in black hypertensives with and without the T594M b-subunit epithelial sodium channel polymorphism [abstract no: TH-FC153]. Journal of the American Society of Nephrology 2006;17(Abstracts):33A-4A. [CENTRAL: CN-00716092].
71. Mortazavi M, Taheri S, Shahidi S, Pourmoghaddas A, Yaraghi MG, Seyrafian S, et al.Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: FP379]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi145. [CENTRAL: CN-00716090].
72. Taheri S, Mortazavi M, Shahidi S, Pourmoghadas A, Garakyaraghi M, Seirafian S, et al.Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases & Transplantation 2009;20(3):392-7. [MEDLINE: 19414940].
73. Toto R, Mortazavi K, Jones K, Roman-Latorre J, Dominguez M, Blackstone S, et al.Combined blockade with the renin-angiotensin-aldosterone system to improve outcomes in diabetics with nephropathy (DN) [abstract no: PUB582]. Journal of the American Society 2005;16:908A.
74. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, et al.Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure 2012;14(6):668-75. [MEDLINE: 22562554].
75. Ando K, Ohtsu H, Arakawa Y, Kubota K, Yamaguchi T, Nagase M, et al.Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical & Experimental 2010;33(6):616-21. [MEDLINE: 20379190].
76. NCT00315016. Eplerenone, ACE inhibition and albuminuria. www.clinicaltrials.gov/ct2/show/NCT00315016 (accessed 23 April 2014).
77. Espinoza FG. Effect of aldosterone antagonism in the reduction of albuminuria and diastolic disfunction of patients with diabetic nephropathy. www.clinicaltrials.gov/ct2/show/NCT00870402 (accessed 23 April 2014).
78. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. Journal of the American Society of Nephrology 2005;16(11):3306-14. [MEDLINE: 16192423].
79. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001;345(12):861-9. [MEDLINE: 11565518].
80. Brenner B. Retarding the progression of renal disease. Kidney International 2003;64(1):370-8. [MEDLINE: 12787440].
81. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al.Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47. [MEDLINE: 17986697].
82. Fritsch Neves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Current Hypertension Reports 2003;5(1):59-65. [MEDLINE: 12530937].
83. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349(9069):1857-63. [MEDLINE: 9217756].
84. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrology Dialysis Transplantation 2005;20(12):2587-93. [MEDLINE: 16204281].
85. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. Journal of Clinical Investigation 1996;98(4):1063-8. [MEDLINE: 8770880].
86. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120].
87. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
88. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. Journal of the American Society of Nephrology 2003;14(9):2395-401. [MEDLINE: 12937319].
89. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al.Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine 2001;135(2):73-87. [MEDLINE: 11453706].
90. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al.Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine 2004;351(6):543-51. [MEDLINE: 15295047].
91. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. New England Journal of Medicine 1994;330(13):877-84. [MEDLINE: 8114857].
92. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification. Annals of Internal Medicine 2003;139(2):137-47.
93. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999;319(7201):24-5. [MEDLINE: 10390455].
94. Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, et al.Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. American Journal of Physiology - Renal Physiology 2008;294(3):F628-37. [MEDLINE: 18094029].
95. Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vascular Health & Risk Management 2011;7:353-63.
96. ONTARGET Investigators. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al.Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008;358(15):1547-59. [MEDLINE: 18378520].
97. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Archives of Internal Medicine 2007;167(18):1930-6. [MEDLINE: 17923591].
98. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 1999;341(10):709-17. [MEDLINE: 10471456].
99. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 2003;348(14):1309-21. [MEDLINE: 12668699].
100. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al.Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney International 2004;65(6):2309-20. [MEDLINE: 15149345].
101. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31(1 Pt 2):451-8. [MEDLINE: 9453344].
102. Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney International 2003;64(6):1947-55. [MEDLINE: 14633117].
103. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al.Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. Journal of Biological Chemistry 1998;273(9):4883-91. [MEDLINE: 9478930].
104. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology 1981;91(3):457-65. [MEDLINE: 7035596].
105. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. Journal of the American Society of Nephrology 2005;16(10):3081-91. [MEDLINE: 16135776].
106. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI:].
107. Navaneethan SD, Nigwekar SU, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI:].
108. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(3):542-51. [MEDLINE: 19261819].